Heartflow, Inc. (NASDAQ:HTFL) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analyst consensus: Heartflow has a consensus rating of "Moderate Buy" from eight analysts (5 buys, 2 holds, 1 sell) with an average 12‑month target price of $37.67.
• Insider selling: Bain Capital Life Sciences sold 2,000,000 shares at $28.05 (~$56.1M), cutting its stake by 16.07; insiders have sold 2,279,027 shares totaling about $63.15M in the past three months.
• Institutional interest & stock metrics: Major funds (Wellington, Baillie Gifford, Vanguard) built sizable new stakes (roughly $164M, $101M and $48.9M respectively), while HTFL trades near $29.05 with a market cap of $2.49B and a 52‑week range of $20.13–$41.22.

Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $37.6667.

A number of research firms have issued reports on HTFL. JPMorgan Chase & Co. decreased their target price on Heartflow from $40.00 to $35.00 and set an "overweight" rating on the stock in a research report on Thursday, March 19th. Canaccord Genuity Group lifted their target price on Heartflow from $40.00 to $43.00 and gave the company a "buy" rating in a research report on Thursday, March 19th. Weiss Ratings reiterated a "sell (d)" rating on shares of Heartflow in a research report on Monday, December 29th. Finally, Wells Fargo & Company decreased their target price on Heartflow from $38.00 to $35.00 and set an "overweight" rating on the stock in a research report on Thursday, March 19th.

Insiders Place Their Bets

In other Heartflow news, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of Heartflow stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $28.05, for a total value of $56,100,000.00. Following the transaction, the insider owned 10,448,158 shares in the company, valued at $293,070,831.90. The trade was a 16.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Julie A. Cullivan sold 9,122 shares of Heartflow stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $25.00, for a total value of $228,050.00. Following the completion of the transaction, the director owned 27,291 shares in the company, valued at approximately $682,275. This represents a 25.05% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 2,279,027 shares of company stock worth $63,146,573.

Institutional Trading of Heartflow

A number of hedge funds have recently made changes to their positions in HTFL. Wellington Management Group LLP acquired a new stake in shares of Heartflow during the third quarter valued at about $164,263,000. Baillie Gifford & Co. acquired a new stake in shares of Heartflow during the third quarter valued at about $101,182,000. Schusterman Interests LLC acquired a new stake in shares of Heartflow during the third quarter valued at about $65,274,000. Capricorn Investment Group LLC acquired a new stake in shares of Heartflow during the fourth quarter valued at about $48,178,000. Finally, Vanguard Group Inc. acquired a new stake in shares of Heartflow during the third quarter valued at about $48,871,000.

Heartflow Stock Performance

HTFL opened at $29.05 on Wednesday. The firm has a market cap of $2.49 billion and a P/E ratio of -14.60. Heartflow has a 52-week low of $20.13 and a 52-week high of $41.22. The business's fifty day moving average is $24.70 and its 200-day moving average is $29.56.

About Heartflow

HeartFlow, Inc NASDAQ: HTFL is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.